AXL and cancer: However, the presence of warfarin following gemcitabine treatment significantly reduced metastatic tumour burden (figure 6J), AXL activation (pAXL) and proliferation (Ki67+) of disseminated cancer cells (online supplemental figure S7I–L), but immune cell infiltration remained unchanged by warfarin (online supplemental figure S7M–Q).